Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Examining alterations in gene expression of prostate cancer cells in presence or absence of PSMA

ABSTRACT: Examining alterations in gene expression of prostate cancer cells in presence or absence of PSMA

PROVIDER: PRJNA412561 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Examining alterations in gene expression of PC3-wt (PSMA -ve) vs PC3-PSMA (PSMA +ve) cells

Project description:Examining alterations in gene expression of PC3-wt (PSMA -ve) vs PC3-PSMA (PSMA +ve) cells

| PRJNA412566 | ENA

Examining alterations in gene expression of LNCaP-Ctrl (PSMA +ve) vs LNCaP-KD (PSMA -ve) cells

Project description:Examining alterations in gene expression of LNCaP-Ctrl (PSMA +ve) vs LNCaP-KD (PSMA -ve) cells

| PRJNA412567 | ENA

Examining alterations in gene expression of PC3-wt (PSMA -ve) vs PC3-PSMA (PSMA +ve) cells

Project description:The biological role of PSMA, a biomarker expressed in prostate cancer and by the neovasculature of solid tumors, remains unknown. Although PSMA processes folates in our duodenum, and in the brain cleaves NAAG to control neuronal signaling, little is known about its role in cancer. We used microarrays to detail the glonal perturbations in gene expression in the absence of PSMA, in order to identify disease-specific driving pathways that may lead to new therapies for cancer.

2017-11-11 | GSE104418 | GEO

Examining alterations in gene expression of LNCaP-Ctrl (PSMA +ve) vs LNCaP-KD (PSMA -ve) cells

2017-11-11 | GSE104417 | GEO

Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer.

Project description:Purpose: Prostate-specific membrane antigen (PSMA) is a cell surface protein expressed in prostate cancer. PSMA targeted imaging and therapeutic approaches have shown clinical benefit, but there are limited data on the heterogeneity of PSMA tissue expression in metastatic castration-resistant prostate cancer (mCRPC) and the mechanisms involved in regulating PSMA expression are not well understood. Results: PSMA expression differed across molecular subtypes of CRPC. In a rapid autopsy cohort in which multiple metastatic sites per patient were sampled, we found that 13/52 (25%) of cases had no PSMA detected and 24/52 (46%) showed heterogeneous PSMA expression between individual metastases. Of these 52 cases, 35 (67%) cases harbored at least one PSMA negative metastatic site. Transcriptomic analyses of PSMA negative tumors revealed distinct differences relative to PSMA-positive tumors including expression of several drug targets. DNA methylation studies showed a tight correlation between CpG methylation and PSMA expression. Treatment with histone deacetylase (HDAC) and DNA methyl transferase (DNMT) inhibitors restored of PSMA expression in vitro and in vivo. Conclusions: Here, we document the extent of PSMA expression diversity in CRPC, highlight novel targeting approaches for PSMA-negative tumors and propose strategies to overcome resistance to PSMA-directed therapies. Collectively, these data can help to guide the clinical development of PSMA targeting agents for diagnosis and therapy.

2023-05-03 | GSE205056 | GEO

Examining alterations in gene expression of prostate cancer cells in presence or absence of PSMA

Project description:This SuperSeries is composed of the SubSeries listed below.

2017-11-11 | GSE104419 | GEO

CD4+ T cells in presence or absence of Ikaros

Project description:CD4+ T cells in presence or absence of Ikaros

| PRJNA662885 | ENA

Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer.

Project description:Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer.

| PRJNA843461 | ENA

Landscape of Prostate-Specific Membrane Antigen Heterogeneity in Metastatic Prostate Cancer [ChIP-Seq]

Project description:Prostate-specific membrane antigen (PSMA) has emerged as an important therapeutic target in metastatic castration-resistant prostate cancer (CRPC). However, not all patients respond to PSMA-targeted therapy, in part due to heterogeneity of tumor expression of the target PSMA. Furthermore, loss of PSMA expression develops in up to 15-20% of patients with CRPC, and the underlying mechanisms remain poorly defined. In this study,To investigate possible epigenetic regulation of PSMA in the context of HOXB13-independent PSMA-suppressed tumors, we performed ChIPseq to evaluate the activation mark Histone H3 Lysine 27 acetylation (H3K27ac) on our previously characterized organoids. Similar to AR-positive, PSMA-positive 22Rv1 cells, the AR-negative, PSMA-positive NEPC model WCM1262 demonstrated H3K27ac at the PSMA (FOLH1) gene promotor corresponding with high PSMA expression, whereas other PSMA-negative NEPC models demonstrated low H3K27ac.

2023-01-30 | GSE221613 | GEO

Global gene expression analysis of MGAS10870 serotype of Group A Streptococcus (Streptococcus pyogenes/GAS) in the absence or presence of 100 µM Manganese

Project description:The goal was to perform global transcriptome analysis on MGAS10870 serotype to investigate and compare the gene expression alterations between ΔmtsR mutant to WT or WT grown in the presence or absence of 100 µM Manganese (MnCl2) to WT grown in the presence of 100µM Manganese (MnCl2)

2019-08-27 | GSE128534 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data